Why GLP-1 Agonists Work Where Absorption Blockers Failed
Semaglutide and tirzepatide produce 15-25% weight loss not by blocking absorption but by mimicking the body's own satiety hormone, suppressing appetite centrally and slowing gastric emptying — working with the body's regulatory loops rather than against them.
GLP-1 agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) achieve 15-25% body weight loss with a tolerable side-effect profile, succeeding where every absorption-blocking drug class failed. Their mechanism is the key to understanding why. They do not interfere with nutrient absorption. Instead they exploit three pathways the body already uses to self-regulate after a meal. First, central appetite suppression: stimulating POMC neurons in the hypothalamus while inhibiting orexigenic NPY/AgRP neurons — the brain registers "not hungry." Second, slowed gastric emptying, which produces satiety from delayed digestion (food still gets absorbed, just later). Third, peripheral satiety signaling by mimicking endogenous GLP-1, the hormone the gut releases naturally after eating. The deeper lesson is mechanistic: these drugs speak to the body in its own language, using receptors and feedback loops that evolved to expect exactly this signal. There is no mismatch between drug action and the body's homeostatic response, so collateral damage stays bounded. Real side effects exist — nausea, early GI upset, occasional gastroparesis, rare pancreatitis concerns — but they are order-of-magnitude milder than what fen-phen or rimonabant produced. Contrast this with bariatric surgery, the structural analog of absorption blocking. Roux-en-Y gastric bypass physically reroutes food past most of the small intestine, forcing malabsorption. It works for weight loss, and it demonstrates the cost of fighting the body's structure: 30-70% of patients develop protein-calorie deficiency over time; B12, folate, iron, calcium, vitamin D, copper, and zinc deficiencies are common; bone loss is significant; complication rates run 15-25%; lifelong supplementation is mandatory. The current obesity-drug pipeline doubles down on the hormone-mimetic strategy rather than returning to absorption blocking: dual GIP-GLP-1 agonists, GLP-1 plus amylin analog combinations, and triple GLP-1/GIP/glucagon agonists in late-stage trials. The directional consensus is to signal the body better, not block it. Informational, not medical advice.